nach oben

03.05.2024 | Research

Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas

verfasst von: Ilah Shin, Yongsik Sim, Seo Hee Choi, Yae Won Park, Narae Lee, Sung Soo Ahn, Jong Hee Chang, Se Hoon Kim, Seung-Koo Lee

Erschienen in: Journal of Neuro-Oncology

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is lack of comprehensive analysis evaluating the impact of clinical, molecular, imaging, and surgical data on survival of patients with gliomatosis cerebri (GC). This study aimed to investigate prognostic factors of GC in adult-type diffuse glioma patients.

Methods

Retrospective chart and imaging review was performed in 99 GC patients from adult-type diffuse glioma (among 1,211 patients; 6 oligodendroglioma, 16 IDH-mutant astrocytoma, and 77 IDH-wildtype glioblastoma) from a single institution between 2005 and 2021. Predictors of overall survival (OS) of entire patients and IDH-wildtype glioblastoma patients were determined.

Results

The median OS was 16.7 months (95% confidence interval [CI] 14.2–22.2) in entire patients and 14.3 months (95% CI 12.2–61.9) in IDH-wildtype glioblastoma patients. In entire patients, KPS (hazard ratio [HR] = 0.98, P = 0.004), no 1p/19q codeletion (HR = 10.75, P = 0.019), MGMTp methylation (HR = 0.54, P = 0.028), and hemorrhage (HR = 3.45, P = 0.001) were independent prognostic factors on multivariable analysis. In IDH-wildtype glioblastoma patients, KPS (HR = 2.24, P = 0.075) was the only independent prognostic factor on multivariable analysis. In subgroup of IDH-wildtype glioblastoma with CE tumors, total resection of CE tumor did not remain as a significant prognostic factor (HR = 1.13, P = 0.685).

Conclusions

The prognosis of GC patients is determined by its underlying molecular type and patient performance status. Compared with diffuse glioma without GC, aggressive surgery of CE tumor in GC patients does not improve survival.

Nur mit Berechtigung zugänglich

Nevin S (1938) Gliomatosis cerebri. Brain 61:170–191. https://doi.org/10.1093/brain/61.2.170CrossRef

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4CrossRefPubMedCentralPubMed

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106CrossRefPubMedCentralPubMed

Ranjan S, Warren KE (2017) Gliomatosis Cerebri: Current Understanding and Controversies. Front Oncol 7:165. https://doi.org/10.3389/fonc.2017.00165CrossRefPubMedCentralPubMed

Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, Sanson M (2006) Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 76:201–205. https://doi.org/10.1007/s11060-005-5263-0CrossRefPubMed

Chen S, Tanaka S, Giannini C, Morris J, Yan ES, Buckner J, Lachance DH, Parney IF (2013) Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol 112:267–275. https://doi.org/10.1007/s11060-013-1058-xCrossRefPubMedCentralPubMed

Carroll KT, Hirshman B, Ali MA, Alattar AA, Brandel MG, Lochte B, Lanman T, Carter B, Chen CC (2017) Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis. World Neurosurg 103:186–193. https://doi.org/10.1016/j.wneu.2017.03.103CrossRefPubMed

Karschnia P, Young JS, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Weller M, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Berger MS, Chang SM, van den Bent M, Tonn J-C (2022) Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro Oncol 25:940–954. https://doi.org/10.1093/neuonc/noac193CrossRefPubMedCentral

10.

Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde T, Selt F, Sturm D, Kool M, Hummel M, Bewerunge-Hudler M, Mawrin C, Schüller U, Jungk C, Wick A, Witt O, Platten M, Herold-Mende C, Unterberg A, Pfister SM, Wick W, von Deimling A (2016) Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol 131:903–910. https://doi.org/10.1007/s00401-015-1519-8CrossRefPubMed

11.

Na K, Kim HS, Shim HS, Chang JH, Kang SG, Kim SH (2019) Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. J Neurooncol 142:445–454. https://doi.org/10.1007/s11060-019-03114-1CrossRefPubMed

12.

Herrlinger U, Jones DT, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M (2016) Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 131:309–319CrossRefPubMed

13.

Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn JC (2023) Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group. Neuro Oncol 25:1672–1685. https://doi.org/10.1093/neuonc/noad074CrossRefPubMedCentralPubMed

14.

Karschnia P, Dietrich J, Bruno F, Dono A, Juenger ST, Teske N, Young JS, Sciortino T, Häni L, van den Bent M, Weller M, Vogelbaum MA, Morshed RA, Haddad AF, Molinaro AM, Tandon N, Beck J, Schnell O, Bello L, Hervey-Jumper S, Thon N, Grau SJ, Esquenazi Y, Rudà R, Chang SM, Berger MS, Cahill DP, Tonn JC (2023) Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ('low grade appearance’) - a report of the RANO resect group. Neuro Oncol. https://doi.org/10.1093/neuonc/noad160CrossRefPubMedCentralPubMed

15.

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186. https://doi.org/10.1038/s41571-020-00447-zCrossRefPubMed

16.

Kim YZ, Kim C-Y, Lim J, Sung KS, Lee J, Oh H-J, Kang S-G, Kang S-H, Kong D-S, Kim SH, Kim S-H, Kim SH, Kim YJ, Kim EH, Kim IA, Kim HS, Roh TH, Park J-S, Park HJ, Song SW, Yang SH, Yoon W-S, Yoon HI, Lee S-T, Lee S-W, Lee YS, Wee CW, Chang JH, Jung T-Y, Jung HL, Cho JH, Choi SH, Choi HS, Hong JB, Lim DH, Chung D-S (2019) The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01. Brain Tumor Res Treat 7:1–9CrossRefPubMedCentralPubMed

17.

R Development Core Team (2010) R: A language and environment for statistical computing. 4.3.2 edn. R Fundation for Statistical Computing; 2019 Vienna, Austria. https://www.R-project.org

18.

Davis C (2014) SurvMisc: Miscellaneous functions for survival data. R package version 0.4.2 edn. https://github.com/dardisco/survMisc

19.

Rajz GG, Nass D, Talianski E, Pfeffer R, Spiegelmann R, Cohen ZR (2012) Presentation patterns and outcome of gliomatosis cerebri. Oncol Lett 3:209–213. https://doi.org/10.3892/ol.2011.445CrossRefPubMed

20.

Vates GE, Chang S, Lamborn KR, Prados M, Berger MS (2003) Gliomatosis cerebri: a review of 22 cases. Neurosurgery 53:261–271. https://doi.org/10.1227/01.neu.0000073527.20655.e6

21.

Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH (2003) Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys 56:1137–1146. https://doi.org/10.1016/s0360-3016(03)00293-1CrossRefPubMed

22.

Kurokawa R, Kurokawa M, Baba A, Ota Y, Pinarbasi E, Camelo-Piragua S, Capizzano AA, Liao E, Srinivasan A, Moritani T (2022) Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors. Radiographics 42:1474–1493. https://doi.org/10.1148/rg.210236CrossRefPubMed

23.

Georgakis MK, Spinos D, Pourtsidis A, Psyrri A, Panourias IG, Sgouros S, Petridou ET (2018) Incidence and survival of gliomatosis cerebri: a population-based cancer registration study. J Neurooncol 138:341–349. https://doi.org/10.1007/s11060-018-2802-zCrossRefPubMed

24.

Doig D, Thorne L, Rees J, Fersht N, Kosmin M, Brandner S, Jäger HR, Thust S (2023) Clinical, Imaging and Neurogenetic Features of Patients with Gliomatosis Cerebri Referred to a Tertiary Neuro-Oncology Centre. J Personalized Med 13:222CrossRef

25.

Georgakis MK, Tsivgoulis G, Spinos D, Liaskas A, Herrlinger U, Petridou ET (2018) Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis. World Neurosurg 120:e818–e854. https://doi.org/10.1016/j.wneu.2018.08.173CrossRefPubMed

26.

Berzero G, Di Stefano AL, Ronchi S, Bielle F, Villa C, Guillerm E, Capelle L, Mathon B, Laurenge A, Giry M, Schmitt Y, Marie Y, Idbaih A, Hoang-Xuan K, Delattre J-Y, Mokhtari K, Sanson M (2020) IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955–966. https://doi.org/10.1093/neuonc/noaa258CrossRefPubMedCentral

27.

Liang J, Lv X, Lu C, Ye X, Chen X, Fu J, Luo C, Zhao Y (2020) Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of Gliomas. BMC Cancer 20:35. https://doi.org/10.1186/s12885-019-6511-6CrossRefPubMedCentralPubMed

28.

Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39–51. https://doi.org/10.1038/nrneurol.2009.197CrossRefPubMed

29.

Kinslow CJ, Rae AI, Taparra K, Kumar P, Siegelin MD, Grinband J, Gill BJA, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Horowitz DP, Kachnic LA, Neugut AI, Yu JB, Cheng SK, Wang TJC (2023) MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clin Cancer Res 29:4399–4407. https://doi.org/10.1158/1078-0432.Ccr-23-1295CrossRefPubMedCentralPubMed

30.

Zimmerman RA, Bilaniuk LT (1980) Computed tomography of acute intratumoral hemorrhage. Radiology 135:355–359. https://doi.org/10.1148/radiology.135.2.7367626CrossRefPubMed

31.

Wakai S, Yamakawa K, Manaka S, Takakura K (1982) Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 10:437–444. https://doi.org/10.1227/00006123-198204000-00004CrossRefPubMed

32.

Choi G, Park DH, Kang SH, Chung YG (2013) Glioma mimicking a hypertensive intracerebral hemorrhage. J Korean Neurosurg Soc 54:125–127. https://doi.org/10.3340/jkns.2013.54.2.125CrossRefPubMedCentralPubMed

33.

Kaloshi G, Everhard S, Laigle-Donadey F, Marie Y, Navarro S, Mokhtari K, Idbaih A, Ducray F, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M (2008) Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology 70:590–595. https://doi.org/10.1212/01.wnl.0000299896.65604.aeCrossRefPubMed

34.

Park S, Suh YL, Nam DH, Kim ST (2009) Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 28:73–82. https://doi.org/10.5414/npp28073CrossRefPubMed

35.

Kong DS, Kim ST, Lee JI, Suh YL, Lim DH, Kim WS, Kwon KH, Park K, Kim JH, Nam DH (2010) Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC Cancer 10:424. https://doi.org/10.1186/1471-2407-10-424CrossRefPubMedCentralPubMed

36.

Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T (2010) Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. Neurosurg Rev 34:197–208. https://doi.org/10.1007/s10143-010-0306-1CrossRefPubMed

37.

Kim K, Chie EK, Park HJ, Kim DG, Jung HW, Park SH, Kim IH (2014) Exclusive radiotherapy for gliomatosis cerebri: long-term follow-up at a single institution. Clin Transl Oncol 16:829–833. https://doi.org/10.1007/s12094-013-1156-4CrossRefPubMed

38.

Anghileri E, Schettino C, Pollo B, Farinotti M, Silvani A, Paterra R, Patanè M, DiMeco F, Bruzzone MG, Eoli M, Cuccarini V (2020) Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. Neurol Sci 41:2111–2120. https://doi.org/10.1007/s10072-020-04288-7CrossRefPubMed

39.

Georgakis MK, Tsivgoulis G, Pourtsidis A, Petridou ET (2019) Gliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients. J Child Neurol 34:394–401. https://doi.org/10.1177/0883073819836551CrossRefPubMed

40.

Young JS, Morshed RA, Hervey-Jumper SL, Berger MS (2023) The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions. Neuro Oncol 25:2117–2133. https://doi.org/10.1093/neuonc/noad133CrossRefPubMed

Titel: Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas
verfasst von: Ilah Shin
Yongsik Sim
Seo Hee Choi
Yae Won Park
Narae Lee
Sung Soo Ahn
Jong Hee Chang
Se Hoon Kim
Seung-Koo Lee
Publikationsdatum: 03.05.2024
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-024-04656-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen